IRIS
ESPOSITO, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.801
EU - Europa 3.051
AS - Asia 2.745
SA - Sud America 358
Continente sconosciuto - Info sul continente non disponibili 213
AF - Africa 47
OC - Oceania 4
Totale 13.219
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.581
SG - Singapore 1.310
RU - Federazione Russa 782
IT - Italia 740
IE - Irlanda 698
CN - Cina 551
HK - Hong Kong 314
BR - Brasile 291
VN - Vietnam 257
DE - Germania 171
UA - Ucraina 157
FR - Francia 125
BD - Bangladesh 118
CA - Canada 114
FI - Finlandia 97
GB - Regno Unito 93
SE - Svezia 58
IN - India 43
MX - Messico 31
TR - Turchia 31
JP - Giappone 24
LT - Lituania 24
AR - Argentina 19
ID - Indonesia 17
NL - Olanda 17
BE - Belgio 16
HN - Honduras 16
CR - Costa Rica 15
PL - Polonia 15
CO - Colombia 14
IQ - Iraq 14
ES - Italia 13
ZA - Sudafrica 13
AT - Austria 9
CZ - Repubblica Ceca 8
JM - Giamaica 8
VE - Venezuela 8
NP - Nepal 7
PK - Pakistan 7
EC - Ecuador 6
GT - Guatemala 6
PH - Filippine 6
PR - Porto Rico 6
SA - Arabia Saudita 6
CL - Cile 5
EE - Estonia 5
MA - Marocco 5
MY - Malesia 5
PE - Perù 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
CW - ???statistics.table.value.countryCode.CW??? 4
DZ - Algeria 4
KR - Corea 4
NI - Nicaragua 4
PY - Paraguay 4
SC - Seychelles 4
SV - El Salvador 4
TH - Thailandia 4
UZ - Uzbekistan 4
BO - Bolivia 3
HU - Ungheria 3
RO - Romania 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
AO - Angola 2
AU - Australia 2
AZ - Azerbaigian 2
BG - Bulgaria 2
DK - Danimarca 2
EG - Egitto 2
GA - Gabon 2
GP - Guadalupe 2
HR - Croazia 2
IL - Israele 2
JO - Giordania 2
KE - Kenya 2
KN - Saint Kitts e Nevis 2
OM - Oman 2
PT - Portogallo 2
RS - Serbia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AG - Antigua e Barbuda 1
BB - Barbados 1
BF - Burkina Faso 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
BZ - Belize 1
CD - Congo 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GD - Grenada 1
GE - Georgia 1
GM - Gambi 1
GN - Guinea 1
Totale 12.996
Salva come PNG Salva come JPEG
Città #
San Jose 856
Dallas 733
Singapore 716
Dublin 696
Jacksonville 614
Ashburn 586
Council Bluffs 523
Chandler 469
Santa Clara 318
Hong Kong 306
The Dalles 202
Boardman 156
Moscow 154
New York 150
Milan 140
Beijing 115
Lawrence 102
Princeton 102
Los Angeles 87
Ho Chi Minh City 75
Nanjing 75
Ann Arbor 71
Rome 71
Wilmington 66
Hanoi 64
Lappeenranta 56
Dearborn 55
Lauterbourg 47
Munich 39
Naples 38
São Paulo 38
Orem 32
Columbus 31
Shenyang 24
Chicago 23
Miano 23
Helsinki 22
Montreal 22
Nanchang 22
Toronto 22
London 21
Phoenix 21
Tokyo 21
Atlanta 20
San Francisco 20
Bar Harbor 19
Brooklyn 19
North Bergen 19
Buffalo 18
Florence 18
Jinan 18
Hebei 17
Houston 17
Denver 16
Frankfurt am Main 16
Jiaxing 16
Brussels 15
Hefei 15
Chennai 14
Des Moines 14
Turku 14
Vilnius 14
Bari 13
Boston 13
Manchester 13
Turin 13
Warsaw 13
Da Nang 12
Haiphong 12
Izmir 12
San Mateo 12
Amsterdam 11
San José 11
Bologna 10
Brasília 10
Catania 10
Changsha 10
Mexico City 10
Palermo 10
Seattle 10
Stockholm 10
Nuremberg 9
Woodbridge 9
Assago 8
Brno 8
Curitiba 8
Hampton 8
Mumbai 8
Norwalk 8
Dhaka 7
Falkenstein 7
Genoa 7
Jakarta 7
Johannesburg 7
Kunming 7
Newark 7
Ningbo 7
Paris 7
Pescara 7
San Pedro Sula 7
Totale 8.681
Salva come PNG Salva come JPEG
Nome #
Exploring the interplay of atopic dermatitis severity with sleep and mental health: a case-control study in adult patients 162
Short-term effectiveness of guselkumab in psoriatic arthritis patients and axial involvement: results from a real-life multicentre cohort 151
Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment. 144
The role of insomnia in the vulnerability to depressive and anxiety symptoms in atopic dermatitis adult patients 143
Management of Cutaneous Squamous Cell Carcinoma of the Scalp in Kidney Transplant Recipients 139
Nail and enthesis assessment in patients with psoriatic disease by high frequency ultrasonography: findings from a single-centre cross-sectional study 136
Frequency of melanocytic nevi in psoriatic patients is related to treatment and not to disease severity 134
CONTINUOUS TREATMENT OF PLAQUE-TYPE PSORIASIS WITH ETANERCEPT: AN OBSERVATIONAL LONG-TERM EXPERIENCE 131
Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis 129
AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History 127
A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy 125
Impact of COVID-19 Pandemic on Delay of Melanoma Diagnosis: A Systematic Review and Meta-Analysis 123
A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis 123
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations 119
Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience 117
Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: A 24-week real-life experience 112
Potential Role of Cytochrome c and Tryptase in Psoriasis and Psoriatic Arthritis Pathogenesis: Focus on Resistance to Apoptosis and Oxidative Stress 111
Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study 110
Cytokine profile characterization of naïve patients with psoriasis and psoriatic arthritis: implications for a pathogenic disease continuum 108
Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study 108
Brodalumab for severe hidradenitis suppurativa: a case of clinico-radiologic improvement and literature review 107
Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. 104
Muir-Torre syndrome with fatal outcome 104
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year. 103
Interobserver agreement on dermoscopic features of pigmented basal cell carcinoma 101
Systemic treatment: Ciclosporin 101
Treatment of erythrodermic psoriasis with etanercept 101
Histopathology of the skin in rheumatic diseases 101
Cutaneous body image in psoriasis: The role of attachment style and alexithymia 101
Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience 100
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study 100
Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis 99
Dermatiti da Piogeni o Piodermiti 99
Consensus on the place in therapy of TNF-α inhibitors in the treatment of patients with chronic plaque psoriasis 97
Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations 96
Interobserver agreement on dermoscopic features of pigmented basal cell carcinoma 95
Combination therapy with etanercept in psoriasis: Retrospective analysis of efficacy and safety outcomes from real-life practice 95
An Italian study on psoriasis and depression 95
Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study—IL AD (Italian Landscape Atopic Dermatitis) 94
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic 94
Influence and variation of the body mass index (BMI) in patients treated with etanercept for plaque-type psoriasis 93
Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: A multicenter retrospective study 92
Treatment of erytrodermic psoriasis with etanercept 92
INFLUENCE AND VARIATION OF THE BODY MASS INDEX IN PATIENTS TREATED WITH ETANERCEPT FOR PLAQUE-TYPE PSORIASIS 92
Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis 92
Dimethyl Fumarate's Effectiveness and Safety in Psoriasis: A Real-Life Experience During the COVID-19 Pandemic 92
Satisfaction and attitudes toward systemic treatments for psoriasis: A cross-sectional study 92
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis 92
Treatment of early stage mycosis fungoides with topical bexarotene 91
Involvement of Ig heavy chain HS1,2-A enhancer*2 allele in dermatitis herpetiformis, plaque psoriasis and psoriatic arthritis 91
PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study 91
A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years 90
Haplotypes associated with alleles of the immunoglobulin heavy chain enhancer HS1,2 of the 3¢ regulatory region in patients with psor- iatic arthritis 90
High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: Efficacy, safety and impact on patients' quality of life 90
Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis 90
Depressive symptoms and insecure attachment predict disability and quality of life in psoriasis independently from disease severity 90
Psoriasis target therapy: ustekinumab 89
Association between psoriasis and periodontitis, and efficacy of anti-TNF-α therapy: a case series 89
Effects of TNF-α inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients 89
Quality of life 88
Betamethasone valerate dressing is non-inferior to calcipotriol-betamethasone dipropionate ointment in the treatment of patients with mild-to-moderate chronic plaque psoriasis: results of a randomized assessor-blinded multicentre trial 88
Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study 88
Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic 88
Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis 87
Psoriasis and its management in women of childbearing age: Tools to increase awareness in dermatologists and patients 87
A case of generalized pustular psoriasis and arthritis treated with ixekizumab 87
A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis 87
Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: an integrated low-intensity intervention program versus standard-of-care 87
Indoor Daylight Photodynamic Therapy for Actinic Keratosis of the Scalp: Intrapatient Comparison Study of 1 h versus 2 h Exposure Time 86
Survival rate of antitumour necrosis factor- treatments for psoriasis in routine dermatological practice: a multicentre observational study 86
Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. 86
Entecavir and intermittent etanercept therapy in a patient with concurrent hepatitis B virus infection and psoriasis 86
Morbid obesity and psoriasis: Disease remission after laparoscopic sleeve gastrectomy 86
Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis. 85
Self-Assessment Questionnaire on Patient-Physician Concordance on Nevus Self-Count and Models Development to Predict High-Risk Phenotype >50 Nevi 84
Clinical Variants 84
Clinical applications of PPI-TT guidelines on transitioning therapies in the treatment of moderate to severe psoriasis: an expert opinion of central Italy dermatologists 84
Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice 84
Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study 83
PsoBioVax: A multicentric Italian case–control study of the immunological response to anti-SARS-CoV-2 vaccine among psoriatic patients under biological therapy 83
Resolution of idiopathic recurrent pericarditis in a psoriatic arthritis patient treated with etanercept 83
UVA1 Laser in the Treatment of Vitiligo 83
Unresponsiveness to etanercept: is there a common phenotipical profile of patients? 83
Efficacy and safety of infliximab in teh treatment of severe or arthropathic psoriasis: preliminary results 83
Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis 83
Treatment adherence to different etanercept regimens, continuous vs. intermittent, in patients affected by plaque-type psoriasis 82
Efficacy and Safety of Etanercept in Psoriasis after Switching from Other Treatments An Observational Study 82
Clinical markers predictive of primary inefficacy: a "real life" retrospective study in psoriatic patients treated with etanercept. 82
Long-lasting remission of pemphigus vulgaris treated with rituximab 82
Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series 82
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis 81
Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients' clinical characteristics leading to disease relapse 80
Long-term efficacy of etanercept in hidradenitis suppurativa. 80
Dermatiti da piogeni o piodermiti 79
Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis 79
Use of etanercept in patients with psoriasis and concomitant hepatitis C infection 79
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy 79
Ixekizumab as a successful treatment in pediatric generalized pustular psoriasis 78
High-dose initiation of etanercept in plaque psoriasis and psoriatic arthritis: an italian experience 78
The Combination of Dupilumab with Other Monoclonal Antibodies. 77
Totale 9.685
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.062
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.062
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022304 0 0 0 11 24 4 3 25 66 4 37 130
2022/20231.613 121 66 15 139 98 133 5 99 840 10 58 29
2023/2024321 59 25 35 27 25 88 4 7 0 22 6 23
2024/20252.106 52 30 171 66 308 163 329 106 520 61 133 167
2025/20265.252 213 357 512 437 367 252 1.022 354 507 659 444 128
2026/20272.107 219 207 498 1.183 0 0 0 0 0 0 0 0
Totale 13.219